BioSpace News Archive

BioMidwest

Zomedica Announces Achievement of Therapeutic Development Milestones

ZM-012 and ZM-007 are complementary oral formulations of metronidazole targeting the treatment of acute diarrhea in dogs

December 12, 2017
·
7 min read
GN Store Nord: Transactions in Relation to Share Buyback Program - Dec. 12, 2017

The share buyback program has been initiated in order to reduce the company’s share capital and to cover obligations under the long-term incentive program.

December 12, 2017
·
1 min read
Detecting Sleep Apnea: Leti Embeds Sensors in Wristband to Measure Heart Rate and Three Other Indicators

APNEAband provides accurate, real-time detection of sleep-apnea events caused by pauses in breathing or shallow breaths during sleep.

December 12, 2017
·
3 min read
Drug Development

Aptose Presents New Preclinical Data on CG’806 pan-FLT3/pan-BTK Inhibitor at ASH 59th Annual Meeting

Data elucidate unique ability of CG’806 to kill a broad range of AML cells by suppressing multiple pathways, to overcome resistance caused by bone marrow stromal cells, and to act synergistically with other agents.

December 12, 2017
·
7 min read
Galapagos: Transparency Notification - Dec. 12, 2017

Galapagos received a transparency notification from Fidelity Management & Research LLC.

December 12, 2017
·
1 min read
Pharm Country

Fibrocell Announces Closing of $10.5M Underwritten Public Offering

H.C. Wainwright & Co. acted as the sole book-running manager for the Offering.

December 12, 2017
·
4 min read
Investors Initiate Tender Offer to Take BioCanCell Private Ahead of Planned Fundraising Round

Shareholders have until Sunday, December 24th, 2017, at 3:00pm IST to vote their acceptance of the offer.

December 12, 2017
·
3 min read
Drug Development

Agios’ New Data From Ivosidenib Phase I Dose-Escalation and Expansion Trial Demonstrate Durable Responses in Patients With IDH1m Relapsed or Refractory AML

The CR+CRh rate is the primary endpoint of the study.

December 12, 2017
·
11 min read
Ossur Hf: Transactions in Relation to Share Buyback Program - Dec. 12, 2017

The program will end no later than 31 July 2018.

December 12, 2017
·
2 min read
Business

Almirall and Athenex Announce Strategic Partnership for the Treatment of Actinic Keratosis

Athenex will grant to Almirall an exclusive license under the Athenex IP to research, develop and commercialize KX2-391 in the United States of America and European countries, including Russia.

December 12, 2017
·
9 min read